SCHEMBL18787566

CCCCCCCC(=O)Oc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	APLNR	P35414	2/20	0.61

▸	GHSR	Q92847	4/20	0.58

▸	NPY2R	P49146	7/20	0.58

▸	NPY4R	P50391	7/20	0.58

▸	NPY5R	Q15761	7/20	0.58

▸	NPY1R	P25929	5/20	0.58

▸	TFPI	P10646	2/20	0.56

▸	RAMP3	O60896	3/20	0.55

▸	CALCR	P30988	3/20	0.55

▸	GLP1R	P43220	1/20	0.54

▸	GCGR	P47871	1/20	0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29403150	0.94	GHSR (0.66)	APLNRGHSRNPY2RNPY4RNPY5R
SCHEMBL29525147	0.92	APLNR (0.63)	APLNRNPY2RNPY4RNPY5RNPY1R
SCHEMBL29526390	0.90	APLNR (0.64)	APLNRNPY2RNPY4RNPY5RNPY1R
SCHEMBL5498547	0.90	APLNR (0.60)	APLNRGHSRNPY2RNPY4RNPY5R
SCHEMBL30166497	0.90	APLNR (0.62)	APLNRGHSRNPY2RNPY4RNPY5R
SCHEMBL29525492	0.90	APLNR (0.64)	APLNRGHSRTFPI
SCHEMBL29526046	0.89	APLNR (0.64)	APLNRGHSRNPY2RNPY4RNPY5R
SCHEMBL29525577	0.89	APLNR (0.64)	APLNRGHSRNPY2RNPY4RNPY5R
SCHEMBL31656374	0.87	TFPI (0.66)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL16150700	0.86	APLNR (0.64)	APLNRGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20200261541-A1	METHODS OF TREATING MILD BRAIN INJURY	OXEIA BIOPHARMACEUTICALS, INC. (US)	2020-08-20	—	—	US	disclosed
US-20180071367-A1	METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION	OXEIA BIOPHARMACEUTICALS, INC. (US)	2018-03-15	—	—	US	disclosed
US-20170281732-A1	METHODS OF TREATING MILD BRAIN INJURY	OXEIA BIOPHARMACEUTICALS, INC. (US)	2017-10-05	—	—	US	disclosed
US-20170266257-A1	METHODS OF TREATING TRAUMATIC BRAIN INJURY	OXEIA BIOPHARMACEUTICALS, INC. (US)	2017-09-21	—	—	US	disclosed
US-20170121385-A1	METHODS OF TREATING NEURODEGENERATIVE CONDITIONS	OXEIA BIOPHARMACEUTICALS, INC. (US)	2017-05-04	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20170266257-A1	METHODS OF TREATING TRAUMATIC BRAIN INJURY	ATP6V1B2, FABP7, GHSR	APLNR 308/4885GHSR 3/4885NPY2R 10/4885
US-20200261541-A1	METHODS OF TREATING MILD BRAIN INJURY	FABP7, PYGB, ATP6V1B2	APLNR 528/4885GHSR 47/4885NPY2R 39/4885
US-20170121385-A1	METHODS OF TREATING NEURODEGENERATIVE CONDITIONS	HTT, SNCA, NLN	APLNR 413/4885GHSR 64/4885NPY2R 90/4885
US-20180071367-A1	METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION	CRH, PYGB, CHAT	APLNR 904/4885GHSR 10/4885NPY2R 111/4885
US-20170281732-A1	METHODS OF TREATING MILD BRAIN INJURY	ATP6V1B2, GHSR, CRH	APLNR 507/4885GHSR 2/4885NPY2R 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.